ABT stock surges 21.7% year to date on CGM sales growth and robust diagnostics demand, even as FX and macro risks weigh on forecasts.

For patients with T2D, disparities in CGM prescriptions are seen by language preference, with less access for adult patients with non-English language preferences.

In a small cell therapy trial, 10 out of 12 people with type 1 diabetes no longer needed supplemental insulin, even a year after treatment.

GlucoModicum today announced positive outcomes from a clinical performance study of its needle-free continuous glucose ...

Lifecare said on social media that it completed a significant milestone in the development of its continuous glucose monitor ...